Legend Biotech's Cancer Drug, 'The Most Attractive Product,' Set For Growth: Analyst
Legend Biotech's Cancer Drug, 'The Most Attractive Product,' Set For Growth: Analyst
Shares of cell therapy company Legend Biotech Corp (NASDAQ:LEGN) were trading lower on Monday, after being among the top pharma gainers in the first week of June.
6月第一週，細胞治療公司Legend Biotech Corp（NASDAQ: LEGN）的股票成爲漲幅最高的製藥股之一，但週一該股下跌。
The company's Carvykti drug is likely to return to growth and revive investor enthusiasm, according to Truist Securities.
據Truist Securities稱，該公司的Carvykti藥品有望恢復增長並重振投資者熱情。
The Legend Biotech Analyst: Asthika Goonewardene initiated coverage of Legend Biotech with a Buy rating and price target of $88.
榮證券（Truist Securities）的分析師Asthika Goonewardene爲Legend Biotech的股票開出買入評級和88美元目標價。
The Legend Biotech Thesis: In a landmark collaboration with Johnson & Johnson (NYSE:JNJ), the company launched Carvykti, which is "the most attractive product" for treating multiple myeloma, Goonewardene said in the initiation note.
據Goonewardene在此次評級報告中稱，與強生（Johnson & Johnson）形成里程碑式合作，推出了用於治療多發性骨髓瘤的Carvykti，這是該公司“最具吸引力的產品”。
"Our spot survey of CAR-T prescribers indicate intentions to increase Carvykti use at a run-rate that is more than double that of last year," the analyst wrote. Carvykti could generate more than 96% year-on-year growth in sales, "and as a revenue generating biotech, we think this will more favorably impact sentiment on LEGN over binary clinical developments," he added.
“我們對CAR-T處方醫生的現場調查顯示，使用Carvykti的意向年均增長率比去年高出一倍以上，”分析師寫道。Carvykti的銷售額可能增長超過96％，“作爲一家收入型生物科技公司，我們認爲這將對LEGN的情緒產生更有利的影響，超過二元臨床進展，”他補充道。
Cell therapies in Multiple Myeloma are estimated to be worth more than $15 billion in the major Western markets and Carvykti can be an over $5 billion product, Goonewardene further said.
Goonewardene進一步指出，多發性骨髓瘤的細胞治療在西部主要市場的價值超過150億美元，而Carvykti可以成爲超過50億美元的產品。
LEGN Price Action: Shares of Legend Biotech were down 2.5% to $41.38 at the time of publication on Monday.
截至週一發佈時，Legend Biotech的股價下跌2.5％至41.38美元。
譯文內容由第三人軟體翻譯。